These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 74811)
1. [Use of high doses of medroxyprogesterone acetate in the palliative treatment of advanced breast cancer. Clinical experience with 44 cases]. Amadori D; Ravaioli A; Barbanti F Minerva Med; 1977 Dec; 68(59):3967-80. PubMed ID: 74811 [TBL] [Abstract][Full Text] [Related]
2. [Preliminary results of treatment of hormone-dependent metastatic carcinoma of the breast with the bromocriptin-medroxyprogesterone acetate combination]. Mussa A; Dogliotti L; Di Carlo F Minerva Med; 1977 Jun; 68(32):2233-44. PubMed ID: 577604 [TBL] [Abstract][Full Text] [Related]
3. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women. Klaassen DJ; Rapp EF; Hirte WE Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780 [TBL] [Abstract][Full Text] [Related]
4. [Modern prospects in the treatment of cancer of the breast and its metastasis. Medroxyprogesterone in massive doses as an alternative to polychemotherapy]. Pannuti F Minerva Chir; 1977 Oct; 32(19):1211-20. PubMed ID: 593576 [No Abstract] [Full Text] [Related]
5. A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate. Pannuti F; Martoni A; Lenaz GR; Piana E; Nanni P Cancer Treat Rep; 1978 Apr; 62(4):499-504. PubMed ID: 350387 [TBL] [Abstract][Full Text] [Related]
6. [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses]. Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F Minerva Med; 1980 Sep; 71(31):2215-9. PubMed ID: 7422143 [TBL] [Abstract][Full Text] [Related]
7. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results. Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848 [TBL] [Abstract][Full Text] [Related]
8. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients. Pannuti F; Longhi A; Martoni A; Piana E; Baroni M Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702 [TBL] [Abstract][Full Text] [Related]
9. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer]. Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090 [TBL] [Abstract][Full Text] [Related]
10. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results. Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237 [No Abstract] [Full Text] [Related]
11. [Hormonal therapy with androgenic steroids in diffuse malignant neoplasms of the breast]. Massidda B; Mascia V; Broccia G; Pasqualucci S; Deplano W; Desogus A; Luxi G; Pellegrini A Minerva Med; 1977 Feb; 68(4):235-41. PubMed ID: 320501 [TBL] [Abstract][Full Text] [Related]
12. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer]. Yoshida M; Murai H; Miura S Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345 [TBL] [Abstract][Full Text] [Related]
13. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers]. Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy with progestins and tamoxifen in advanced breast cancer: A preliminary report. Trodella L; Ausilli-Cefaro GP; Turriziani A; Saccheri S; Venturo I; Minotti G Am J Clin Oncol; 1982 Oct; 5(5):495-9. PubMed ID: 6217741 [No Abstract] [Full Text] [Related]
15. High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer. Goss PE; Ashley S; Powles TJ; Coombes RC Cancer Treat Rep; 1986 Jun; 70(6):777-9. PubMed ID: 2942246 [TBL] [Abstract][Full Text] [Related]
16. [Clinical trial of high-dose medroxyprogesterone acetate in advanced breast cancer]. Jiang Z; Song S; Li J Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):71-3. PubMed ID: 7656795 [TBL] [Abstract][Full Text] [Related]
17. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer]. Noguchi S; Yamamoto H; Inaii H; Koyama H Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936 [TBL] [Abstract][Full Text] [Related]
18. [Overall evaluation of the results of treatment of metastatic carcinomas of the breast with high doses of MAP combined with bromocryptin]. Mussa A; Dogliotti L; Di Carlo F Minerva Med; 1980 Feb; 71(6):391-400. PubMed ID: 7360379 [No Abstract] [Full Text] [Related]
19. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force]. Wander HE; Nagel GA; Blossey HC Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600 [TBL] [Abstract][Full Text] [Related]
20. [High-dosed gestagen therapy of the metastatic mammary carcinoma (author's transl)]. Firusian N; Becher R Strahlentherapie; 1981 Dec; 157(12):808-12. PubMed ID: 7330909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]